Isostearate is a type of ester derived from isostearic acid, a branched-chain fatty acid. It is commonly used in cosmetics and personal care products due to its emollient properties. Isostearates provide a smooth, silky feel to the skin and help to improve its hydration. They are also used as thickeners and stabilizers in various formulations. The synthesis of isostearates typically involves the esterification of isostearic acid with an alcohol, such as glycerol or sorbitol. Isostearates are generally considered safe for topical use and have low allergenic potential. They are often studied for their ability to improve skin barrier function, reduce transepidermal water loss, and enhance the delivery of other active ingredients.'
16-methylheptadecanoic acid : A methyl-branched fatty acid that is heptadecanoic acid (margaric acid) substituted by a methyl group at position 16. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 21859 |
| CHEMBL ID | 1865303 |
| CHEBI ID | 84896 |
| SCHEMBL ID | 15489 |
| MeSH ID | M0121756 |
| Synonym |
|---|
| 16-methylheptadecanoic acid |
| heptadecanoic acid, 16-methyl- |
| einecs 220-336-3 |
| ISA , |
| isostearic acid, >=97% (capillary gc) |
| LMFA01020014 |
| isostearic acid |
| isooctadecanoic acid |
| 16-methyl-heptadecanoic acid |
| 16-methyl margaric acid |
| NCGC00164392-01 |
| 30399-84-9 |
| 2724-58-5 |
| NCGC00164392-02 |
| dsstox_gsid_27963 |
| dsstox_cid_7963 |
| dsstox_rid_78624 |
| cas-30399-84-9 |
| NCGC00255115-01 |
| tox21_302276 |
| C20356 |
| 16-methylmargaric acid |
| unii-lzm5xa0ill |
| prisorine 3509 |
| lzm5xa0ill , |
| (+)-isostearic acid |
| emersol 873 |
| SCHEMBL15489 |
| XDOFQFKRPWOURC-UHFFFAOYSA-N |
| CHEMBL1865303 |
| chebi:84896 , |
| W-109211 |
| DTXSID1040790 |
| AKOS027320244 |
| J-016709 |
| Q27158161 |
| D92986 |
| AS-57253 |
| 16-methylheptadecanoicacid |
| CS-0185665 |
| HY-W127433 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the present study, safe and effective ionic liquids for transdermal absorption were obtained as salts generated by a neutralization reaction between highly biocompatible aliphatic carboxylic acids (octanoic acid or isostearic acid) and aliphatic amines (diisopropanolamine or triisopropanolamine) (Medrx Co." | ( The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers. Kubota, K; Shibata, A; Yamaguchi, T, 2016) | 0.43 |
| Class | Description |
|---|---|
| branched-chain saturated fatty acid | Any saturated fatty acid with a carbon side-chain or isopropyl termination. |
| long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
| methyl-branched fatty acid | Any branched-chain fatty acid containing methyl branches only. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 35.5742 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 31.7055 | 0.0025 | 41.7960 | 15,848.9004 | AID1347397 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 24.5412 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 54.4827 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.3365 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 27.6810 | 0.0002 | 21.2231 | 8,912.5098 | AID588515; AID743035; AID743063 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 15.3553 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 11.6310 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 51.5202 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 12.2080 | 0.0002 | 29.3054 | 16,493.5996 | AID588513; AID588514; AID743069 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 44.9342 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 18.9588 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 46.9181 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.9410 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 15.8968 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 126.7930 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 13.6854 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 37.2684 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 39.8107 | 0.0158 | 23.5273 | 44.6684 | AID651778 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (59.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||